This is highlighted in a recent report in which a single mutation among 24 (4.2%) predicted for MHC II presentation was found to be a target of CD4+ T cells and was capable of enhancing prophylactic CD8+ T cell immunity in a highly immunogenic sarcoma model (71). This evidence concerns the gene CD8A and sarcoma.